241 related articles for article (PubMed ID: 32039686)
1. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
Sherpa C; Le Grice SFJ
Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
[TBL] [Abstract][Full Text] [Related]
2. Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
Ding C; Patel D; Ma Y; Mann JFS; Wu J; Gao Y
Front Immunol; 2021; 12():697683. PubMed ID: 34354709
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Lin A; Balazs AB
Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
[TBL] [Abstract][Full Text] [Related]
4. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
Thavarajah JJ; Hønge BL; Wejse CM
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
[TBL] [Abstract][Full Text] [Related]
5. Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.
Phelps M; Balazs AB
Front Immunol; 2021; 12():734304. PubMed ID: 34603314
[TBL] [Abstract][Full Text] [Related]
6. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
Ahmad M; Ahmed OM; Schnepp B; Johnson PR
Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
[TBL] [Abstract][Full Text] [Related]
7. Broadly Neutralizing Antibodies for HIV-1 Prevention.
Walsh SR; Seaman MS
Front Immunol; 2021; 12():712122. PubMed ID: 34354713
[TBL] [Abstract][Full Text] [Related]
8. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
Brady JM; Baltimore D; Balazs AB
Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
[TBL] [Abstract][Full Text] [Related]
9. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV.
Martinez-Navio JM; Fuchs SP; Mendes DE; Rakasz EG; Gao G; Lifson JD; Desrosiers RC
Front Immunol; 2020; 11():449. PubMed ID: 32256496
[TBL] [Abstract][Full Text] [Related]
11. Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs.
Seaman MS; Bilska M; Ghantous F; Eaton A; LaBranche CC; Greene K; Gao H; Weiner JA; Ackerman ME; Garber DA; Rosenberg YJ; Sarzotti-Kelsoe M; Montefiori DC
J Immunol Methods; 2020 Apr; 479():112736. PubMed ID: 31917969
[TBL] [Abstract][Full Text] [Related]
12. Expression of HIV-1 broadly neutralizing antibodies mediated by recombinant adeno-associated virus 8 in vitro and in vivo.
Yu Y; Fu L; Jiang X; Guan S; Kuai Z; Kong W; Shi Y; Shan Y
Mol Immunol; 2016 Dec; 80():68-77. PubMed ID: 27835755
[TBL] [Abstract][Full Text] [Related]
13. Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
Hsu DC; Mellors JW; Vasan S
Front Immunol; 2021; 12():710044. PubMed ID: 34322136
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV-1 Antibodies: An Update.
Promsote W; DeMouth ME; Almasri CG; Pegu A
BioDrugs; 2020 Apr; 34(2):121-132. PubMed ID: 32152957
[TBL] [Abstract][Full Text] [Related]
15. Antibody-based protection against HIV infection by vectored immunoprophylaxis.
Balazs AB; Chen J; Hong CM; Rao DS; Yang L; Baltimore D
Nature; 2011 Nov; 481(7379):81-4. PubMed ID: 22139420
[TBL] [Abstract][Full Text] [Related]
16. Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression.
Martinez-Navio JM; Fuchs SP; Pantry SN; Lauer WA; Duggan NN; Keele BF; Rakasz EG; Gao G; Lifson JD; Desrosiers RC
Immunity; 2019 Mar; 50(3):567-575.e5. PubMed ID: 30850342
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
Mahomed S
Clin Microbiol Rev; 2024 Jun; 37(2):e0015222. PubMed ID: 38687039
[TBL] [Abstract][Full Text] [Related]
18. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
Pegu A; Xu L; DeMouth ME; Fabozzi G; March K; Almasri CG; Cully MD; Wang K; Yang ES; Dias J; Fennessey CM; Hataye J; Wei RR; Rao E; Casazza JP; Promsote W; Asokan M; McKee K; Schmidt SD; Chen X; Liu C; Shi W; Geng H; Foulds KE; Kao SF; Noe A; Li H; Shaw GM; Zhou T; Petrovas C; Todd JP; Keele BF; Lifson JD; Doria-Rose NA; Koup RA; Yang ZY; Nabel GJ; Mascola JR
Cell Rep; 2022 Jan; 38(1):110199. PubMed ID: 34986348
[TBL] [Abstract][Full Text] [Related]
19. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.
Wu X; Guo J; Niu M; An M; Liu L; Wang H; Jin X; Zhang Q; Lam KS; Wu T; Wang H; Wang Q; Du Y; Li J; Cheng L; Tang HY; Shang H; Zhang L; Zhou P; Chen Z
J Clin Invest; 2018 Jun; 128(6):2239-2251. PubMed ID: 29461979
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus delivery of broadly neutralizing antibodies.
Schnepp BC; Johnson PR
Curr Opin HIV AIDS; 2014 May; 9(3):250-6. PubMed ID: 24638019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
